STOCK TITAN

[Form 4] United States Cellular Corporation 5.500% Senior Notes due 2070 Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Amendment No. 3 to Schedule 13D updates the equity position of Swedish investor Frankenius Equity AB and its founder Paul Frankenius in TriSalus Life Sciences (TLSI).

  • The reporting persons converted 230,000 Series A preferred shares into 759,000 common shares under the issuer’s 3.3-for-1 exchange offer that closed 31 Jul 2025.
  • Total beneficial ownership now stands at 6,989,748 common shares, equal to 14.0 % of the 49.79 million shares outstanding post-exchange.
  • Control structure: Frankenius Equity lists shared voting/dispositive power; Paul Frankenius reports sole power over the same shares, reflecting his ultimate ownership of the entity.

No additional transactions occurred in the last 60 days, and the filing notes no criminal or civil proceedings against the reporting persons. The Schedule 13D/A is purely a disclosure of ownership; it does not outline plans for mergers, asset sales or other corporate actions.

Emendamento n. 3 al Schedule 13D aggiorna la posizione azionaria dell'investitore svedese Frankenius Equity AB e del suo fondatore Paul Frankenius in TriSalus Life Sciences (TLSI).

  • Le persone segnalanti hanno convertito 230.000 azioni privilegiate di Serie A in 759.000 azioni ordinarie tramite l'offerta di scambio 3,3 per 1 dell'emittente, chiusa il 31 luglio 2025.
  • La proprietà effettiva totale è ora di 6.989.748 azioni ordinarie, pari al 14,0% delle 49,79 milioni di azioni in circolazione dopo lo scambio.
  • Struttura di controllo: Frankenius Equity detiene il potere condiviso di voto e disposizione; Paul Frankenius riporta il potere esclusivo sulle stesse azioni, riflettendo la sua proprietà finale dell'entità.

Non sono state effettuate ulteriori transazioni negli ultimi 60 giorni e la documentazione non segnala procedimenti penali o civili contro le persone segnalanti. Il Schedule 13D/A è una semplice comunicazione di proprietà; non indica piani per fusioni, vendite di asset o altre azioni societarie.

Enmienda N° 3 al Schedule 13D actualiza la posición accionaria del inversor sueco Frankenius Equity AB y su fundador Paul Frankenius en TriSalus Life Sciences (TLSI).

  • Las personas informantes convirtieron 230,000 acciones preferentes Serie A en 759,000 acciones ordinarias bajo la oferta de intercambio 3.3 por 1 del emisor, que cerró el 31 de julio de 2025.
  • La propiedad beneficiaria total ahora es de 6,989,748 acciones ordinarias, equivalente al 14.0 % de las 49.79 millones de acciones en circulación después del intercambio.
  • Estructura de control: Frankenius Equity posee poder compartido de voto y disposición; Paul Frankenius reporta poder exclusivo sobre las mismas acciones, reflejando su propiedad final de la entidad.

No se registraron transacciones adicionales en los últimos 60 días y el informe no menciona procedimientos penales o civiles contra las personas informantes. El Schedule 13D/A es únicamente una divulgación de propiedad; no detalla planes para fusiones, ventas de activos u otras acciones corporativas.

Schedule 13D 수정안 제3호는 스웨덴 투자자 Frankenius Equity AB와 그 설립자 Paul Frankenius의 TriSalus Life Sciences (TLSI) 지분 현황을 업데이트합니다.

  • 보고자는 2025년 7월 31일 종료된 발행사의 3.3대 1 교환 제안을 통해 230,000주의 시리즈 A 우선주를 759,000주의 보통주로 전환했습니다.
  • 총 실질 소유 지분은 현재 6,989,748주 보통주로, 교환 후 발행 주식 4,979만 주의 14.0%에 해당합니다.
  • 지배 구조: Frankenius Equity는 공동 의결권 및 처분 권한을 보유하며, Paul Frankenius는 동일 주식에 대해 단독 권한을 보고하여 최종 소유권을 반영합니다.

최근 60일간 추가 거래는 없었으며, 보고서에는 보고자에 대한 형사 또는 민사 소송이 없다고 명시되어 있습니다. Schedule 13D/A는 단순 소유권 공개이며 합병, 자산 매각 또는 기타 기업 행위 계획을 포함하지 않습니다.

Amendement n° 3 au Schedule 13D met à jour la position en actions de l'investisseur suédois Frankenius Equity AB et de son fondateur Paul Frankenius dans TriSalus Life Sciences (TLSI).

  • Les personnes déclarantes ont converti 230 000 actions privilégiées de Série A en 759 000 actions ordinaires dans le cadre de l'offre d'échange 3,3 pour 1 de l'émetteur, clôturée le 31 juillet 2025.
  • La propriété bénéficiaire totale s'élève désormais à 6 989 748 actions ordinaires, soit 14,0 % des 49,79 millions d'actions en circulation après l'échange.
  • Structure de contrôle : Frankenius Equity détient un pouvoir de vote et de disposition partagé ; Paul Frankenius déclare un pouvoir exclusif sur ces mêmes actions, reflétant sa propriété finale de l'entité.

Aucune transaction supplémentaire n'a eu lieu au cours des 60 derniers jours, et le dépôt ne signale aucune procédure pénale ou civile à l'encontre des personnes déclarantes. Le Schedule 13D/A est uniquement une divulgation de propriété ; il ne détaille aucun projet de fusion, de vente d'actifs ou d'autres actions corporatives.

Nachtrag Nr. 3 zum Schedule 13D aktualisiert die Beteiligungsposition des schwedischen Investors Frankenius Equity AB und seines Gründers Paul Frankenius an TriSalus Life Sciences (TLSI).

  • Die meldepflichtigen Personen haben 230.000 Vorzugsaktien der Serie A in 759.000 Stammaktien umgewandelt im Rahmen des 3,3-zu-1 Umtauschangebots des Emittenten, das am 31. Juli 2025 abgeschlossen wurde.
  • Die Gesamtbeteiligung beträgt nun 6.989.748 Stammaktien, was 14,0 % von 49,79 Millionen nach dem Umtausch ausstehenden Aktien entspricht.
  • Kontrollstruktur: Frankenius Equity hält gemeinsame Stimm- und Verfügungsrechte; Paul Frankenius meldet alleinige Rechte über dieselben Aktien, was seine endgültige Eigentümerschaft an der Gesellschaft widerspiegelt.

In den letzten 60 Tagen gab es keine weiteren Transaktionen, und die Meldung vermerkt keine straf- oder zivilrechtlichen Verfahren gegen die meldepflichtigen Personen. Das Schedule 13D/A dient lediglich der Offenlegung der Eigentumsverhältnisse; es enthält keine Pläne für Fusionen, Vermögensverkäufe oder sonstige Unternehmensmaßnahmen.

Positive
  • Frankenius Equity now owns 6.99 million common shares, representing 14 % of TLSI, signalling sustained shareholder commitment.
  • Preferred-for-common exchange completed, simplifying capital structure by reducing preferred stock.
Negative
  • None.

Insights

TL;DR: 14 % stake confirmed after preferred-for-common swap; disclosure neutral for valuation.

The amendment shows Frankenius Equity’s continued commitment, converting preferred into common to maintain a sizeable 6.99 m-share position. Although a double-digit holding can influence governance, the transaction is an even exchange that neither injects new capital nor alters cash flows. Free float increases slightly, but overall dilution was already signalled in the S-4. Given the absence of new buying or selling, and no stated activist intent, the filing is informational rather than market-moving.

Emendamento n. 3 al Schedule 13D aggiorna la posizione azionaria dell'investitore svedese Frankenius Equity AB e del suo fondatore Paul Frankenius in TriSalus Life Sciences (TLSI).

  • Le persone segnalanti hanno convertito 230.000 azioni privilegiate di Serie A in 759.000 azioni ordinarie tramite l'offerta di scambio 3,3 per 1 dell'emittente, chiusa il 31 luglio 2025.
  • La proprietà effettiva totale è ora di 6.989.748 azioni ordinarie, pari al 14,0% delle 49,79 milioni di azioni in circolazione dopo lo scambio.
  • Struttura di controllo: Frankenius Equity detiene il potere condiviso di voto e disposizione; Paul Frankenius riporta il potere esclusivo sulle stesse azioni, riflettendo la sua proprietà finale dell'entità.

Non sono state effettuate ulteriori transazioni negli ultimi 60 giorni e la documentazione non segnala procedimenti penali o civili contro le persone segnalanti. Il Schedule 13D/A è una semplice comunicazione di proprietà; non indica piani per fusioni, vendite di asset o altre azioni societarie.

Enmienda N° 3 al Schedule 13D actualiza la posición accionaria del inversor sueco Frankenius Equity AB y su fundador Paul Frankenius en TriSalus Life Sciences (TLSI).

  • Las personas informantes convirtieron 230,000 acciones preferentes Serie A en 759,000 acciones ordinarias bajo la oferta de intercambio 3.3 por 1 del emisor, que cerró el 31 de julio de 2025.
  • La propiedad beneficiaria total ahora es de 6,989,748 acciones ordinarias, equivalente al 14.0 % de las 49.79 millones de acciones en circulación después del intercambio.
  • Estructura de control: Frankenius Equity posee poder compartido de voto y disposición; Paul Frankenius reporta poder exclusivo sobre las mismas acciones, reflejando su propiedad final de la entidad.

No se registraron transacciones adicionales en los últimos 60 días y el informe no menciona procedimientos penales o civiles contra las personas informantes. El Schedule 13D/A es únicamente una divulgación de propiedad; no detalla planes para fusiones, ventas de activos u otras acciones corporativas.

Schedule 13D 수정안 제3호는 스웨덴 투자자 Frankenius Equity AB와 그 설립자 Paul Frankenius의 TriSalus Life Sciences (TLSI) 지분 현황을 업데이트합니다.

  • 보고자는 2025년 7월 31일 종료된 발행사의 3.3대 1 교환 제안을 통해 230,000주의 시리즈 A 우선주를 759,000주의 보통주로 전환했습니다.
  • 총 실질 소유 지분은 현재 6,989,748주 보통주로, 교환 후 발행 주식 4,979만 주의 14.0%에 해당합니다.
  • 지배 구조: Frankenius Equity는 공동 의결권 및 처분 권한을 보유하며, Paul Frankenius는 동일 주식에 대해 단독 권한을 보고하여 최종 소유권을 반영합니다.

최근 60일간 추가 거래는 없었으며, 보고서에는 보고자에 대한 형사 또는 민사 소송이 없다고 명시되어 있습니다. Schedule 13D/A는 단순 소유권 공개이며 합병, 자산 매각 또는 기타 기업 행위 계획을 포함하지 않습니다.

Amendement n° 3 au Schedule 13D met à jour la position en actions de l'investisseur suédois Frankenius Equity AB et de son fondateur Paul Frankenius dans TriSalus Life Sciences (TLSI).

  • Les personnes déclarantes ont converti 230 000 actions privilégiées de Série A en 759 000 actions ordinaires dans le cadre de l'offre d'échange 3,3 pour 1 de l'émetteur, clôturée le 31 juillet 2025.
  • La propriété bénéficiaire totale s'élève désormais à 6 989 748 actions ordinaires, soit 14,0 % des 49,79 millions d'actions en circulation après l'échange.
  • Structure de contrôle : Frankenius Equity détient un pouvoir de vote et de disposition partagé ; Paul Frankenius déclare un pouvoir exclusif sur ces mêmes actions, reflétant sa propriété finale de l'entité.

Aucune transaction supplémentaire n'a eu lieu au cours des 60 derniers jours, et le dépôt ne signale aucune procédure pénale ou civile à l'encontre des personnes déclarantes. Le Schedule 13D/A est uniquement une divulgation de propriété ; il ne détaille aucun projet de fusion, de vente d'actifs ou d'autres actions corporatives.

Nachtrag Nr. 3 zum Schedule 13D aktualisiert die Beteiligungsposition des schwedischen Investors Frankenius Equity AB und seines Gründers Paul Frankenius an TriSalus Life Sciences (TLSI).

  • Die meldepflichtigen Personen haben 230.000 Vorzugsaktien der Serie A in 759.000 Stammaktien umgewandelt im Rahmen des 3,3-zu-1 Umtauschangebots des Emittenten, das am 31. Juli 2025 abgeschlossen wurde.
  • Die Gesamtbeteiligung beträgt nun 6.989.748 Stammaktien, was 14,0 % von 49,79 Millionen nach dem Umtausch ausstehenden Aktien entspricht.
  • Kontrollstruktur: Frankenius Equity hält gemeinsame Stimm- und Verfügungsrechte; Paul Frankenius meldet alleinige Rechte über dieselben Aktien, was seine endgültige Eigentümerschaft an der Gesellschaft widerspiegelt.

In den letzten 60 Tagen gab es keine weiteren Transaktionen, und die Meldung vermerkt keine straf- oder zivilrechtlichen Verfahren gegen die meldepflichtigen Personen. Das Schedule 13D/A dient lediglich der Offenlegung der Eigentumsverhältnisse; es enthält keine Pläne für Fusionen, Vermögensverkäufe oder sonstige Unternehmensmaßnahmen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HARCZAK HARRY J JR

(Last) (First) (Middle)
500 W. MADISON STREET, SUITE 810

(Street)
CHICAGO IL 60661

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ARRAY DIGITAL INFRASTRUCTURE, INC. [ USM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 08/01/2025 A(1) 1,960 A $73.5 21,334 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares acquired pursuant to a compensation plan for non-employee directors.
Remarks:
Julie D. Mathews, by power of atty 08/04/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many TriSalus (TLSI) shares does Frankenius Equity now own?

The filing reports 6,989,748 common shares beneficially owned.

What percentage of TriSalus common stock does 6.99 million shares represent?

It equals 14.0 % of the outstanding common shares post-exchange.

Why did Frankenius Equity receive additional common shares?

They exchanged 230,000 preferred shares for 759,000 common shares under a 3.3-for-1 offer that closed 31 Jul 2025.

Does the Schedule 13D/A indicate plans for control of TriSalus?

No. The amendment is purely an ownership disclosure; it states no plans for mergers, asset sales or other actions.

Who holds voting power over the reported TLSI shares?

Paul Frankenius has sole voting and dispositive power despite the shares being registered to Frankenius Equity AB.
United States

NYSE:UZE

UZE Rankings

UZE Latest SEC Filings

UZE Stock Data

20.00M
Wireless Telecommunications Carriers (except Satellite)
Radiotelephone Communications
Link
CHICAGO